Oxford Biomedica, Homology Medicines to create AAV manufacturing JV in US
Oxford Biomedica, a UK-based gene and cell therapy company, has agreed to form a joint venture (JV) to undertake an adeno-associated virus (AAV) manufacturing and innovation business in the US with Homology Medicines. The joint venture has been named — Oxford Biomedica Solutions. As per the terms of the agreement, Oxford Biomedica will pay $130 […]